GlassScriptPhysician profile
Andrew P Porter
NPI 1083002570
$2,542.77
in general payments reported to CMS, 2019-2025
24 companies · $878 in 2025
The $878 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $537 · 2022: $89.66 · 2023: $309 · 2024: $729 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,916.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $581.03 | 2023-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $443.69 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $326.48 | 2021-2025 | |
| Boston Scientific Corporation | $204.95 | 2024-2025 | Watchman Flx |
| Amgen INC. | $142.94 | 2021-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $141.77 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $128.69 | 2023-2024 | Verquvo, Winrevair |
| Bridgebio Pharma, INC. | $104.31 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $72.30 | 2025 | |
| Amarin Pharma, INC. | $42.37 | 2021 | |
| Abiomed | $42.04 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $40.41 | 2025 | Opsumit, Uptravi |
| Abbott Laboratories | $37.12 | 2022 | |
| Scpharmaceuticals INC. | $34.12 | 2024-2025 | |
| Philips North America LLC | $29.85 | 2025 | Ecc Solutions |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29.52 | 2025 | Dupixent |
| Lundbeck LLC | $23.63 | 2021 | |
| Pfizer INC. | $22.24 | 2025 | |
| Medtronic, INC. | $18.39 | 2021 | |
| Arcutis Biotherapeutics, INC. | $16.54 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.33 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $15.06 | 2024 | Nexletol |
| Novo Nordisk INC | $14.93 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.06 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.